Supplemental material
Open access
18,522
Views
0
CrossRef citations to date
0
Altmetric
Perspectives
Antibodies to watch in 2024
Silvia Cresciolia Business Intelligence Research, The Antibody Society, Inc., Framingham, MA, UShttps://orcid.org/0000-0002-1909-5957View further author information
, Hélène Kaplonb Translational Medicine Department, Institut de Recherches Internationales Servier, Gif-sur-Yvette, Francehttps://orcid.org/0000-0002-5597-2195View further author information
, Alicia Chenowethc St. John’s Institute of Dermatology, School of Basic & Medical Biosciences, King’s College London, London, UKhttps://orcid.org/0000-0002-2736-9268View further author information
, Lin Wangd Regeneron, Formulation Development, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, UShttps://orcid.org/0009-0005-7958-9894View further author information
, Jyothsna Visweswaraiahe Drug Creation, Seismic Therapeutic, Cambridge, MA, UShttps://orcid.org/0000-0002-6181-2438View further author information
& Janice M. Reicherta Business Intelligence Research, The Antibody Society, Inc., Framingham, MA, USCorrespondence[email protected]
https://orcid.org/0000-0003-0400-1951View further author information
https://orcid.org/0000-0003-0400-1951View further author information
Article: 2297450
|
Received 10 Dec 2023, Accepted 15 Dec 2023, Published online: 05 Jan 2024
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.